The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial

Blood

Volumn 92, Issue 7, 1998, Pages 2322-2333

  Grimwade, David ^b   Walker, Helen ^b   Oliver, Fiona ^b   Wheatley, Keith ^b   Harrison, Christine ^b   Harrison, Georgina ^b   Rees, John ^b   Hann, Ian ^b   Stevens, Richard ^b   Burnett, Alan ^b   Goldstone, Anthony ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0032188805     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.7.2322     Document Type: Article

References (49)

1. Berger R, Bernheim A, Ochoa-Noguera ME, Daniel MT, Valensi F, Sigaux F, Flandrin G, Boiron M: Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients. Cancer Genet Cytogenet 28:293, 1987
2. Samuels BL, Larson RA, Le Beau MM, Daly KM, Bitter MA, Vardiman JW, Baker CM, Rowley JD, Golomb HM: Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 2:79, 1988
3. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ: Cytogenetic pattern in acute myelogenous leukemia: A major reproducible determinant of outcome. Leukemia 2:403, 1988
4. Fenaux P, Preudhomme C, Lai JL, Morel P, Beuscart R, Bauters F: Cytogenetics and their prognostic significance in acute myeloid leukaemia: A report on 283 cases. Br J Haematol 73:61, 1989
5. Arthur DC, Berger R, Golomb HM, Swansbury GJ, Reeves BR, Alimena G, van den Berghe H, Bloomfield CD, de la Chapelle A, Dewald GW, Garson OM, Hagemeijer A, Kaneko Y, Mitelman F, Pierre RV, Ruutu T, Sakurai M, Lawler SD, Rowley JD: The clinical significance of karyotype in acute myelogenous leukemia. Sixth International Workshop on Chromosomes in Leukemia (1987). Cancer Genet Cytogenet 40:203, 1989
6. Marosi C, Köller U, Koller-Weber E, Schwarzinger I, Schneider B, Jäger U, Vahls P, Nowotny H, Pirc-Danoewinata H, Steger G, Kreiner G, Wagner B, Lechner K, Lutz D, Bettelheim P, Haas OA: Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 61:14, 1992
7. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, van den Berghe H, Bloomfield CD, de la Chapelle A, Dewald G, Garson OM, Hagemeijer A, Mitelman F, Rowley JD, Sakurai M: Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 73:1, 1994
8. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Lerous D, Huguet-Rigal F, Stoppa A-M, Marit G, Molina L, Michallet M, Maraninchi D, Attal M, Reiffers J: Prognostic significance of karyotype in de novo adult myeloid leukemia. Leukemia 9:1491, 1995
9. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM, Garson OM, Peterson BA, Sakurai M, Alimena G, Berger R, Rowley JD, Ruutu T, Mitelman F, Dewald GW, Swansbury J: Long-term survival of patients with acute myeloid leukemia. A third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 80:2191, 1997
10. Hann IM, Stevens RF, Goldstone AH, Rees JKH, Wheatley K, Gray RG, Burnett AK: Randomised comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML 10). Blood 89:2311, 1997
11. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukaemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 94:557, 1996
12. Mitelman F: ISCN: An international system for human cytogenetic nomenclature. Basel, Switzerland, Karger, 1995
13. Langabeer SE, Grimwade D, Walker H, Rogers JR, Burnett AK, Goldstone AH, Linch DC: A study to determine whether trisomy 8, deleted 9q and trisomy 22 are markers of cryptic rearrangements of PML/RARα, AML1/ETO and CBFB/MYH11 respectively in acute myeloid leukaemia. Br J Haematol 101:338, 1998
14. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA: A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet 2:113, 1992
15. Waring PM, Cleary ML: Disruption of a homolog of trithorax by 11q23 translocations: Leukemogenic and transcriptional implications. Curr Top Microbiol Immunol 220:1, 1997
16. Nakamura T, Alder H, Gu Y, Prasad R, Canaani O, Kamada N, Gale RP, Lange B, Crist WM, Nowell PC, Croce CM, Canaani E: Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs. Proc Natl Acad Sci USA 90:4631, 1993
17. Chaplin T, Ayton P, Bernard OA, Saha V, Delia Valle V, Million J, Gregorini A, Lillington D, Berger R, Young BD: A novel class of zinc finger/leucine zipper genes identified from the molecular cloning of the t(10;11) translocation in acute leukemia. Blood 85:1435, 1995
18. Martinez-Climent JA, Espinosa R, Thirman MJ, Le Beau MM, Rowley JD: Abnormalities of chromosome band-11q23 and the MLL gene in pediatric myelomonocytic and monoblastic leukemias -identification of the t(9;11) as an indicator of long survival. J Pediatr Hematol Oncol 17:277, 1995
19. Mrozek K, Heinonen K, Lawrence D, Carroll AJ, Koduru PRK, Rao KW, Strout MP, Hutchison RE, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD: Adult patients with de-novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23 - A Cancer and Leukemia Group B study. Blood 90:4532, 1997
20. Hiorns LR, Swansbury GJ, Mehta J, Min T, Dainton MG, Treleaven J, Powles RL, Catovsky D: Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia. Br J Haematol 96:314, 1997
21. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Löffler H, Büchner T, Fonatsch C: Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): A report on 50 patients. Br J Haematol 94:493, 1996
22. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD: Secondary cytogenetic changes in acute promyelocytic leukemia, prognostic importance in patients treated with chemotherapy alone and association with the intron-3 breakpoint of the PML gene - a Cancer and Leukemia Group-B study. J Clin Oncol 15:1786, 1997
23. Schoch C, Haase D, Haferlach T, Gudat H, Büchner T, Freund M, Link H, Lengfelder E, Wandt H, Sauerland MC, Löffler H, Fonatsch C: Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22:q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia 10:1288, 1996
24. Ferrant A, Doyen C, Delannoy A, Straetmans N, Martial P, Mineur P, Bosly A, van den Berghe H, Michaux JL: Karyotype in acute myeloblastic leukemia: Prognostic significance in a prospective study assessing bone marrow transplantation in first remission. Bone Marrow Transplant 15:685, 1995
25. Gale RP, Horowitz MM, Weiner RS, Ash RC, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J, Rimm AA, Rowlings PA, Sandberg AA, Sobocinski KA, Veum-Stone J, Bortin MM: Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 16:203, 1995
26. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, Reiffers J, Visani G, Sanz MA, Boogaerts MA, Lowenberg B, Gorin NC: Karyotype in acute myeloblastic leukemia: Prognostic significance for bone marrow transplantation in first remission: A European Group for Blood and Marrow Transplantation study. Blood 90:2931, 1997
27. Veldman T, Vignon C, Schröck E, Rowley JD, Ried T: Hidden chromosome abnormalities in hematological malignancies detected by multicolor spectral karyotyping. Nat Genet 15:406, 1997
28. Nucifora G, Rowley JD: AMLI and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 86:1, 1995
29. Lopingco MC, Perkins AS: Molecular analysis of Evil, a zinc finger oncogene involved in myeloid leukemia. Curr Top Microbiol Immunol 211:211, 1996
30. Zent C, Kim N, Hiebert S, Zhang D-E, Tenen DG, Rowley JD, Nucifora G: Rearrangement of the AML1/CBFα2 gene in myeloid leukemia with the 3;21 translocation: Expression of co-existing multiple chimeric genes with similar functions as transcriptional repressers, but with opposite tumorigenic properties. Curr Top Microbiol Immunol 211:243, 1996
31. Seeker-Walker LM, Mehta A, Bain B: Abnormalities of 3q21 and 3q26 in myeloid malignancy: A United Kingdom Cancer Cytogenetic Group study. Br J Haematol 91:490, 1995
32. Russel M, List A, Greenberg P, Woodward S, Glinsmann B, Parganas E, Ihle J, Taetle R: Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. Blood 84:1243, 1994
33. Bower M, Parry P, Carter M, Lillington DM, Amess J, Lister TA, Evans G, Young BD: Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood 84:3776, 1994
34. Schichman SA, Caligiuri MA, Gu Y, Strout MP, Canaani E, Bloomfield CD, Croce CM: All-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 91:6236, 1994
35. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AW, Rao PN, Herzig GP, Powell BC, Ruutu T, Schiffer CA, Bloomfield CD: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55, 1998
36. Hiorns LR, Min T, Swansbury GJ, Zelent A, Dyer MJS, Catovsky D: Interstitial insertion of retinoic acid receptor-α gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood 83:2946, 1994
37. Lafage-Pochitaloff M, Alcalay M, Brunel V, Longo L, Sainty D, Simonetti J, Birg F, Pelicci PG: Acute promyelocytic leukemia cases with nonreciprocal PML/RARα or RARα/PML fusion genes. Blood 85:1169, 1995
38. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walker H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876, 1997
39. Maruyama F, Yang P, Stass SA, Cork A, Freireich EJ, Lee M-S, Chang K-S: Detection of the AML1/ETO fusion transcript in the t(8;21) masked translocation in acute myelogenous leukemia. Cancer Res 53:4449, 1993
40. Nucifora G, Dickenstein JI, Torbenson V, Rowley JD, Vardiman JW: Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 8:1533, 1994
41. Langabeer SE, Walker H, Rogers JR, Burnett AK, Wheatley K, Swirsky D, Goldstone AH, Linch DC: Incidence of AML 1/ETO fusion transcripts in patients entered into the MRC AML trials. Br J Haematol 99:925, 1997
42. Andrieu V, Radford-Weiss I, Troussard X, Chane C, Valensi F, Guesnu M, Haddad E, Viguier F, Dreyfus F, Varet B, Flandrin G, Macintyre E: Molecular detection of t(8;21)/AML1-ETO in AML M1/M2: Correlation with cytogenetics, morphology and immunophenotype. Br J Haematol 92:855, 1996
43. Langabeer SE, Walker H, Gale RE, Wheatley K, Burnett AK, Goldstone AH, Linch DC: Frequency of CBFβ/MYH11 fusion tran- scripts in patients entered into the U.K. MRC AML trials. Br J Haematol 96:736, 1997
44. Grimwade D, Langabeer S, Gorman P, Howe K, Duprez E, Walker H, Wheatley K, Goldstone A, Burnett A, Solomon E: Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome. Blood 90:271a, 1997 (suppl 1, abstr)
45. Head D, Kopecky KJ, Weick J, Files J, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum F: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
46. Fenaux P, Chastang C, Castaigne S, Archimbaud E, Sanz M, Link H, Guerci A, Fegueux N, Zittoun R, Stoppa AM, Travade P, Lamy T, Maloisel F, Sadoun A, San Miguel J, Veil A, Rayon C, Conde E, Fey M, Bordessoule D, Ganser A, Bowen D, Dreyfus F, Huguet F, Tilly H, Guy H, Auzanneau G, Chomienne C, Degos L: Treatment of newly diagnosed acute promyelocytic leukemia (APL) with all-transretinoic acid (ATRA) followed by intensive chemotherapy (CT). Updated results of the European group. Blood 84:379a, 1994 (suppl 1, abstr)
47. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021, 1997
48. Bloomfield CD, Lawrence D, Arthur DC, Berg DT, Schiffer CA, Mayer RJ: Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 84:111a, 1994 (abstr, suppl 1)
49. Rowe JM, Liesveld JL: Treatment and prognostic factors in acute myeloid leukaemia. Baillière's Clin Haematol 9:87, 1996